Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
Colorcon
Express Scripts
Medtronic

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR IMURAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Imuran

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001789 ↗ BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-06-01 The purpose of this study is to investigate whether the experimental drug BG9588 can be used to treat lupus nephritis more effectively and with less toxicity than standard treatments, including cyclophosphamide (Cytoxan), azothioprine (Imuran) and prednisone. The body's immune system naturally produces antibodies to fight foreign substances like bacteria and viruses. In autoimmune diseases like lupus, however, the body makes antibodies that attack its own tissues, causing inflammation and organ damage. Lupus antibodies attack and damage kidney cells. BG9588 can interfere with the production of these antibodies, and therefore, may lessen kidney damage in people with lupus nephritis. This study will look at: how BG9588 enters and leaves the blood and body tissue over time; adverse effects of the drug; and whether treatment with BG9588 can result in less kidney damage than other therapies. Study patients will be receive a 30-minute infusion of BG9588 into a vein every two weeks for three doses and then once every 28 days for four doses. Patients' steroid dosage may be tapered; individual adjustments will be made as required. Patients screened for the study will undergo a physical examination, medical history, various blood and urine tests, as well as complete a quality of life questionnaire. Results of a previous kidney biopsy and chest X ray are also required. Many of these tests will be repeated throughout the study. In a previous animal study, BG9588 treatment of mice with lupus nephritis improved their disease and survival.
NCT00098111 ↗ Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease Terminated Massachusetts General Hospital Phase 3 2005-04-01 The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00104299 ↗ Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Genentech, Inc. Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗ Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Immune Tolerance Network (ITN) Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 ↗ Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Imuran

Condition Name

Condition Name for Imuran
Intervention Trials
Crohn's Disease 8
Lupus Nephritis 5
Ulcerative Colitis 3
Inflammatory Bowel Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Imuran
Intervention Trials
Crohn Disease 10
Nephritis 5
Lupus Nephritis 5
Colitis, Ulcerative 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imuran

Trials by Country

Trials by Country for Imuran
Location Trials
United States 77
Netherlands 7
Canada 7
Italy 4
Australia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Imuran
Location Trials
New York 9
Ohio 8
Minnesota 6
Pennsylvania 6
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imuran

Clinical Trial Phase

Clinical Trial Phase for Imuran
Clinical Trial Phase Trials
Phase 4 6
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Imuran
Clinical Trial Phase Trials
Completed 18
Terminated 8
Unknown status 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imuran

Sponsor Name

Sponsor Name for Imuran
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 3
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 2
University of Pennsylvania 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Imuran
Sponsor Trials
Other 36
Industry 18
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Express Scripts
Medtronic
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.